By Kishore Bhaskar and Ashish SinhaThe pharmaceutical giant Gilea has acquired the rights to a cancer drug developed by biotech company Regeneron Pharmaceuticals.
The deal, which was first reported by the Times of India, is expected to see Gileas medicines enter the Indian market as early as 2020.
Gileam Pharmaceuticals is currently the only Indian company working on the cancer drug and the company has also won the right to develop and sell its own drug for use in developing countries.
Gildan, a manufacturer of vitamins and supplements, has a 20-year deal with Regeneron to sell the cancer treatment in India.
But its drugs have been shown to be very effective in treating many types of cancer.
India is home to around 2.5 million cancer cases per year and around 20 million people are on the waiting list to get treatment.
India has one of the highest death rates for cancer, with around 1,300 people dying of the disease every day.
A major problem with cancer treatment is that it is very expensive.
The country has a $1.6 trillion healthcare bill, making it the second largest in the world.
India spends around $1 billion a year on cancer treatments and drugs, according to the Indian Government.
The pharmaceutical company is hoping to attract Indian patients and doctors who are used to seeing generic drugs in the U.S. and Europe.
According to the Times, Gildans new cancer drug, Gilein, has shown promising results in clinical trials and is on the verge of approval by the Food and Drug Administration (FDA).
It was developed by a company called Regeneron, which is a division of the biotech company Gileac.
GIL is the brand name of Gileax, a company that GileAc was founded by.
In addition to its cancer drug deal, GIL also acquired the biotechnology company Axon Pharma for $3.2 billion, according the Times.
Axon has developed several other drugs for the treatment of cancer, including one that is being used in China.
Axo had also developed a cancer vaccine that was used in South Africa, India, Japan and the United Kingdom.
It was also awarded the contract to manufacture the drug in India earlier this year.
Gil’s drug could have significant impact in India and could be a major boon to the country, as Gileys cancer drug costs are expected to come down as the country transitions to a national healthcare system.
The drugs are also expected to reduce the demand for expensive cancer drugs.
India accounts for around 2 million cancer deaths each year.
India’s national cancer plan was launched in 2015, but its main goal is to reduce deaths by 40% by 2030.
A national plan for cancer is expected in 2021, but it has yet to be implemented.
India currently spends around 50% of its budget on cancer treatment.
Gili’s acquisition of Regeneron’s drug will allow the pharmaceutical company to increase the drug’s reach in India, where it has a huge market.
Giles drug will be licensed in India by the FDA in 2019 and will be sold to other patients around the world through Gildas online portal.
Gilda is a brand name for Gildanes new cancer treatment, and Gildax, which Gileal was founded to develop.
The drug has a lifespan of around 30 years and is approved for use on patients over the age of 65 in over 100 countries.
According the Times report, the FDA approved Gilda’s drug in March of this year, but the approval process has been ongoing for years.
The FDA approved the drug for the use of patients over 65 years old in India in November of last year, after a yearlong review.
Gail’s DrugGildas new drug will target a rare type of cancer called sarcoma, which attacks the skin, bone marrow, blood vessels and nerves.
The cancer is often fatal, and it is not known whether Gildin’s drug can be as effective against sarcomas.
The company has already had a positive result in a clinical trial in the Indian state of Andhra Pradesh.
Giambattista Vignelli, Gilda’s chief executive, told the Times that Gildins new drug is based on the research from India.
According a Gildon spokesman, the drug is in phase 2 clinical trials in the country.
It has a potential to be ready for commercialisation in the next two years, according Gildons website.
It is also looking at developing the drug as a treatment for multiple cancers in Africa.
In August, Gail and Gilda announced that Gilda had raised a $200 million Series B round, led by the UBS Global Investment Bank.
In November, Gili announced that it had raised $75 million in Series A funding.
The new funding was led by Gildah Capital Management.
Gila has already secured $500 million in funding from other investors.